Zoek in het archief
 
terug

Check the original
News breaking: 2017-09-12

Pharnext geeft presentatie op Global Investment Conference van Rodman & Renshaw

12:56 uur 06-09-2017

Pharnext geeft presentatie op Global Investment Conference van Rodman & Renshaw

PARIJS–(BUSINESS WIRE)– Pharnext SA (Paris:ALPHA) (FR00111911287 – ALPHA), een biofarmaceutisch bedrijf met een vernieuwende benadering van geneesmiddelen door reeds bekende medicijnen te combineren en te herpositioneren, heeft vandaag bekendgemaakt dat de directie van het bedrijf een presentatie geeft op de negentiende Global Investment Conference van Rodman & Renshaw.

De presentatie vindt plaats op:

Datum: dinsdag 12 september 2017

Tijdstip: 17.30 EDT (23.30 CEST)

Locatie: Lotte New York Palace Hotel in New York, New York

 

 

Pharnext to Present at Rodman& Renshaw 19th Annual Global Investment Conference

PARIS–(BUSINESS WIRE)– Regulatory News:

Pharnext SA (Paris:ALPHA) (FR00111911287 – ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced that company management will present a corporate overview at the Rodman & Renshaw 19th Annual Global Investment Conference.

The presentation will take place as follows:

Date: Tuesday, September 12th, 2017

Time: 5:30 pm EDT (11:30 pm CEST)

Venue: Lotte New York Palace Hotel in New York, New York

If you are interested in meeting the Pharnext management team during this event, please send an email to Matthew Shinseki at matthew@sternir.com.

About Pharnext

Pharnext is an advanced clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The Company identifies and develops synergic combinations of repositioned drugs at new optimal lower doses. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team.

The company Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN code: FR00111911287).

For more information, visit www.pharnext.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20170905005711/en/

Contacts

Pharnext

Xavier Paoli, +33 (0)1 41 09 22 30

Chief Commercial Officer

contact@pharnext.com

or

Invest or Relations (Europe)

MC Services AG

Anne Hennecke, +49 211 529252 22

anne.hennecke@mc-services.eu

or

Media Relations (Europe)

ALIZE RP

Caroline Carmagnol

Margaux Pronost

+33 (0)1 44 54 36 64

pharnext@alizerp.com

or

Invest or Relations (U.S.)

Stern Investor Relations, Inc.

Matthew Shinseki, +1 212-362-1200

matthew@sternir.com

or

Media Relations (U.S.)

Russo Partners

Tony Russo

Scott Santiamo

tony.russo@russopartnersllc.com

scott.santiamo@russopartnersll c.com

+1 212-845-4251

+1 718-344-5843

or

Financial Communication (France)

New CAP

Emmanuel Huynh, +33 (0)1 44 71 20 40

pharnext@newcap.eu

Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, die als enige rechtsgeldig is.